<DOC>
	<DOCNO>NCT02193503</DOCNO>
	<brief_summary>The objective assess safety tolerability 6 vaccine dos MVX-ONCO-1 , administer sub-cutaneously ( injection capsule implantation ) , patient advance metastatic solid tumor progression longer amenable standard therapy tumour disease .</brief_summary>
	<brief_title>MVX-ONCO-1 Patients With Solid Tumor</brief_title>
	<detailed_description>Endpoints : Primary : To assess safety parameter include adverse serious adverse event ( incidence , causality , severity ) , local systemic tolerance administer study treatment , change laboratory value vital sign patient solid tumor ; Secondary : measure tumor response use image technique , serological tumor marker , immune monitor metabolic monitoring .</detailed_description>
	<criteria>Male female patient age 18 year old advance metastatic cancer progression various site [ Carcinoma lung ( either small cell nonsmall cell ) , colon , breast , pancreas ( exocrine endocrine ) , stomach , oesophagus , head &amp; neck , thyroid , kidney , bladder , prostate , ovary , uterus ( cervix corpus ) ; Sarcoma soft tissue , bone , uterus , melanoma ; primary brain tumor ] recognize treatment exhaust feasible . Life expectancy : estimate least 4 month . Have participate investigational study receive experimental therapeutic procedure consider interfere study 4 precede week . Have receive chemotherapy treatment 4 preceding week . Serious concomitant health condition organ transplant require immunosuppressive drug , severe psychiatric disorder . History second cancer within last 2 year exception basal cell carcinoma skin localize cervical carcinoma treat curative intent . Patient systemic disease cancer , control usual medication . Therapeutic anticoagulation coumarine continue iv heparin . Lowmolecular weight heparin ( LMWH ) permit long treatment withhold several hour prior subcutaneous implantation . Positive HIV1 , HIV2 , HTLV1 , HTLV2 , hepatitis B surface antigen , hepatitis C antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>gene therapy</keyword>
	<keyword>cell therapy</keyword>
	<keyword>encapsulation</keyword>
</DOC>